GENB — Generate Biomedicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2100782 ·
Last close
$15.15
Market Cap
$1.94B
52W High
$22.67
52W Low
$11.00
ADV30
1,486,223
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 6,314,000 | — | -71,614,000 | -67,255,000 | 561,690,000 | 135,359,000 | 105,645,000 |
| Mar 2026 | 7,224,000 | — | -64,112,000 | -61,446,000 | 625,737,000 | 160,575,000 | 110,936,000 |
| Jun 2025 | 10,130,000 | — | -60,150,000 | -52,429,000 | — | — | — |
| Mar 2025 | 8,818,000 | — | -48,154,000 | -41,685,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-133,564,000
Investing CF
$-184,402,000
Financing CF
$399,451,000
CapEx
$-4,532,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-737,739,000
Inventory
—
Receivables
—
ST Investments
$356,066,000
EBIT TTM
$-105,394,000
Pretax Income TTM
$-105,944,000
Interest Exp TTM
$550,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$26,483,000
EBITDA
$-249,548,000
Free Cash Flow
—
Enterprise Value
$1,622,913,280
Total Cash
$457,415,008
Total Debt
$62,628,000
Shares Out
128,352,436
Trailing EPS
$-2.10
Book Value
$3.56
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,893,000 | -235,065,000 | -203,154,000 | 330,182,000 | 953,379,000 | -615,965,000 | -200,619,000 |
| Dec 2024 | 20,459,000 | -196,939,000 | -173,771,000 | 518,259,000 | 953,349,000 | -434,519,000 | -117,750,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.95B | $32.58 | — |
| NKTR | NEKTAR THERAPEUTICS | $1.95B | $57.06 | — |
| BHVN | Biohaven Ltd. | $1.96B | $12.99 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.97B | $18.67 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.99B | $138.16 | — |
News headlines (Yahoo Finance, 1h cache)
Generate Biomedicines Inc. to Participate in September Investor Conferences
2026-09-08 11:09 · Yahoo
EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says
2026-08-27 23:31 · Yahoo
Cathie Wood Sends a $20 Million Signal on Broadcom Stock
2026-08-27 19:18 · Yahoo
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
2026-08-25 15:10 · Yahoo
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 11:00 · Yahoo
AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
2026-09-08 14:36 · Yahoo
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
2026-08-28 11:59 · Yahoo
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns
2026-08-26 22:16 · Yahoo
Nvidia Holds More Than 122 Million Shares of SPCX Stock After Q2. Barchart Data Shows It’s Making a High-Upside Bet.
2026-08-18 18:56 · Yahoo
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
2026-08-05 15:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.